Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SNTI

SNTI - Senti Biosciences, Inc. Stock Price, Fair Value and News

2.44USD-0.11 (-4.31%)Delayed

Market Summary

SNTI
USD2.44-0.11
Delayed
-4.31%

SNTI Stock Price

View Fullscreen

SNTI RSI Chart

SNTI Valuation

Market Cap

11.2M

Price/Earnings (Trailing)

-0.1

Price/Sales (Trailing)

4.08

Price/Free Cashflow

-0.21

SNTI Price/Sales (Trailing)

SNTI Profitability

Return on Equity

-208.2%

Return on Assets

-114.29%

Free Cashflow Yield

-477.59%

SNTI Fundamentals

SNTI Revenue

Revenue (TTM)

2.7M

Rev. Growth (Yr)

13.61%

Rev. Growth (Qtr)

-100%

SNTI Earnings

Earnings (TTM)

-116.8M

Earnings Growth (Yr)

35.31%

Earnings Growth (Qtr)

82.96%

Breaking Down SNTI Revenue

Last 7 days

-24.4%

Last 30 days

868%

Last 90 days

680.7%

How does SNTI drawdown profile look like?

SNTI Financial Health

Current Ratio

5.79

SNTI Investor Care

Shares Dilution (1Y)

3.59%

Diluted EPS (TTM)

-14.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.7M000
20234.5M4.0M2.6M2.6M
20223.8M4.4M5.0M4.3M
20211.1M1.7M2.2M2.8M
2020000566.0K

Tracking the Latest Insider Buys and Sells of Senti Biosciences, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
rajangam kanya
acquired
-
-
101,000
chief medical & devt. officer
Feb 01, 2024
lu timothy k
acquired
-
-
306,000
ceo and president
Feb 01, 2024
knobelman deborah
acquired
-
-
101,000
chief financial officer
Oct 03, 2022
knobelman deborah
acquired
-
-
30,000
chief financial officer
Jun 08, 2022
epstein david r
acquired
-
-
112,519
-
Jun 08, 2022
farokhzad omid
acquired
-
-
5,750,000
-
Jun 08, 2022
farokhzad omid
acquired
2,500,000
10.00
250,000
-
Jun 08, 2022
farokhzad omid
sold
-
-
-4,518,100
-
Jun 08, 2022
dynamics sponsor llc
acquired
-
-
5,750,000
-
Jun 08, 2022
dynamics sponsor llc
sold
-
-
-6,465,500
-

1–10 of 10

Which funds bought or sold SNTI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 20, 2024
Virtu Financial LLC
new
-
7,000
7,000
-%
May 17, 2024
Artal Group S.A.
sold off
-100
-37,000
-
-%
May 16, 2024
COMERICA BANK
unchanged
-
-14.00
18.00
-%
May 15, 2024
MORGAN STANLEY
new
-
603
603
-%
May 15, 2024
CITADEL ADVISORS LLC
added
80.78
949
29,793
-%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
3,210
3,210
-%
May 15, 2024
NEA Management Company, LLC
unchanged
-
-1,252,160
1,669,100
0.10%
May 15, 2024
BANK OF AMERICA CORP /DE/
reduced
-95.4
-3,368
91.00
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-7.48
-4,485
5,029
-%
May 15, 2024
STATE STREET CORP
unchanged
-
-11,061
14,745
-%

1–10 of 33

Are Funds Buying or Selling SNTI?

Are funds buying SNTI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SNTI
No. of Funds

Unveiling Senti Biosciences, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
woodline partners lp
0%
0
SC 13G/A

Recent SEC filings of Senti Biosciences, Inc.

View All Filings
Date Filed Form Type Document
Jul 17, 2024
8-K
Current Report
Jul 16, 2024
8-K
Current Report
Jul 12, 2024
4
Insider Trading
Jul 12, 2024
4
Insider Trading
Jul 12, 2024
4
Insider Trading
Jul 12, 2024
4
Insider Trading
Jul 12, 2024
8-K
Current Report
May 29, 2024
DEF 14A
DEF 14A
May 29, 2024
ARS
ARS
May 29, 2024
DEFA14A
DEFA14A

Peers (Alternatives to Senti Biosciences, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Senti Biosciences, Inc. News

Latest updates
Yahoo Finance16 Jul 202412:30 pm
InvestorPlace25 Jun 202407:00 am
TradingView22 months ago

Senti Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue-1,461-3389371,28659.001,7661,3581,1047931,10379372.00-
Operating Expenses-1.1%16,30116,47544,21420,57216,25015,35916,51423,12912,86211,67812,5269,7899,214-
  S&GA Expenses-17.5%7,5229,1209,4319,6209,1919,4539,99513,8825,2595,2697,1164,5544,311-
  R&D Expenses23.9%8,7797,0859,09210,9527,0595,9076,5199,2477,6036,4095,4105,2354,903-
Net Income83.0%-12,111-71,058-14,923-18,697-18,722-58,210-16,640-11,552-11,808-10,904-11,406-12,007-21,002-
Net Income Margin11.4%-42.69*-48.18*-42.20*-27.74*-23.53*-22.91*-10.14*-10.48*-12.16*-20.04*-8.98*-11.94*-17.82*-35.09*
Free Cashflow-66.1%-11,697-7,041-17,237-17,344-22,811-17,539-24,337-16,955-17,439-15,956-9,737-1,354-8,571-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q22021Q12021Q12020Q4
Assets-14.5%10211913214416118118920292.0097.0023223223217111048.00
  Current Assets-21.8%56.0071.0079.0063.0081.0010312014445.0060.002.002.002.00--32.00
    Cash Equivalents-34.0%24.0036.0039.0037.0032.0061.0011514038.0059.0074.0083.002.0026.00-31.00
  Net PPE-3.9%24.0025.0026.0059.0059.0051.0047.0036.0024.0012.00-----3.00
Liabilities-12.3%46.0053.0049.0046.0049.0054.0049.0048.0042.0036.008.008.008.0011.0014.0017.00
  Current Liabilities-24.2%10.0013.0010.0010.0013.0018.0016.0018.0018.0015.000.000.000.00--5.00
Shareholder's Equity-16.2%56.0067.0083.0097.00112127140154---5.00-0.00--
  Retained Earnings-5.0%-256-244-225-210-192-173-155-138-126-115-6.52-6.23-6.000.000.00-59.80
  Additional Paid-In Capital0.4%3133113093083043012952935.004.00---0.000.001.00
Accumulated Depreciation14.9%7.006.005.004.003.003.003.002.002.002.00-----1.00
Shares Outstanding0.0%5.005.004.004.004.004.002.001.000.000.000.000.00-1.001.001.00
Float-100.0%-30.00-24.00---75.00---229----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q4
Cashflow From Operations-66.0%-11,682-7,037-15,379-13,675-16,304-9,006-10,136-5,695-10,059-11,971-8,805-934-8,365--
  Share Based Compensation-39.1%1,2582,0644093,4343,7634,2162,2909,225661735626562372--
Cashflow From Investing-114.9%-15.0010121,14218,331-9,497-49,118-14,201-11,260-7,380---230,000-206--
Cashflow From Financing-100.0%-556-23.00281-35.00876-485118,615-455--232,0323,558--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SNTI Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue  
Contract revenue$ 0$ 1,036,000
Grant income0250,000
Total revenue01,286,000
Operating expenses  
Research and development (included related party cost of $3,632 and $—, respectively)8,779,0007,059,000
General and administrative7,522,0009,191,000
Total operating expenses16,301,00016,250,000
Loss from operations(16,301,000)(14,964,000)
Other income (expense)  
Interest income, net331,0001,061,000
Change in fair value of contingent earnout liability059,000
GeneFab sublease income - related party1,461,0000
Other income (expense)0(8,000)
Total other income, net4,190,0001,112,000
Net loss from continuing operations(12,111,000)(13,852,000)
Net loss from discontinued operations0(4,870,000)
Net loss(12,111,000)(18,722,000)
Other comprehensive gain (loss)  
Unrealized gain on investments02,000
Comprehensive loss$ (12,111,000)$ (18,720,000)
Net loss per share, basic and diluted  
Net loss per share from continuing operations, basic (in dollars per share)$ (0.26)$ (0.31)
Net loss per share from continuing operations, diluted (in dollars per share)(0.26)(0.31)
Net income (loss) per share from discontinued operations, basic (in dollars per share)0.00(0.11)
Net loss per share from discontinued operations, diluted (in dollars per share)0(0.11)
Net loss per share, basic (in dollars per share)(0.26)(0.42)
Net loss per share, diluted (in dollars per share)$ (0.26)$ (0.42)
Weighted-average shares outstanding, basic (in shares)45,708,60144,070,974
Weighted-average shares outstanding, diluted (in shares)45,708,60144,070,974
GeneFab Note Receivable  
Other income (expense)  
Change in fair value$ 29,000$ 0
GeneFab Economic Share  
Other income (expense)  
Change in fair value55,0000
GeneFab Option  
Other income (expense)  
Change in fair value$ 2,314,000$ 0

SNTI Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash and cash equivalents$ 23,723$ 35,926
Total current assets55,66671,200
Restricted cash4,0283,522
GeneFab receivable - related party, net of current portion3831,119
Property and equipment, net24,35425,338
Operating lease right-of-use assets15,79716,274
GeneFab Economic Share - related party1,8711,816
Other long-term assets86215
Total assets102,185119,484
Liabilities and Stockholders’ Equity  
Accounts payable1,6241,250
Finance lease liabilities, current portion10097
Early exercise liability, current portion111135
GeneFab sublease deferred income - related party862989
Accrued expenses and other current liabilities2,7345,927
Operating lease liabilities4,1784,031
Current liabilities of discontinued operations0243
Total current liabilities9,60912,672
Operating lease liabilities, net of current portion32,44533,538
Contingent earnout liability2020
GeneFab Option - related party4,0176,331
Early exercise liability, net of current portion010
Total liabilities46,09152,571
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively00
Common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 45,712,821 and 45,700,161 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively55
Additional paid-in capital312,544311,252
Accumulated other comprehensive income00
Accumulated deficit(256,455)(244,344)
Total stockholders’ equity56,09466,913
Total liabilities and stockholders’ equity102,185119,484
Nonrelated Party  
Assets  
Accounts receivable76112
Prepaid expenses and other current assets2,7202,783
Related Party  
Assets  
Accounts receivable17,84717,592
Prepaid expenses and other current assets$ 11,300$ 14,787
SNTI
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEsentibio.com
 INDUSTRYBiotechnology
 EMPLOYEES122

Senti Biosciences, Inc. Frequently Asked Questions


What is the ticker symbol for Senti Biosciences, Inc.? What does SNTI stand for in stocks?

SNTI is the stock ticker symbol of Senti Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Senti Biosciences, Inc. (SNTI)?

As of Fri Jul 19 2024, market cap of Senti Biosciences, Inc. is 110.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers.

What is the fair value of SNTI stock?

You can check SNTI's fair value in chart for subscribers. The fair value of Senti Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Senti Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNTI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Senti Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNTI is over valued or under valued. Whether Senti Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Senti Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNTI.

What is Senti Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, SNTI's PE ratio (Price to Earnings) is -0.95 and Price to Sales (PS) ratio is 40.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNTI PE ratio will change depending on the future growth rate expectations of investors.